Commercialization of Spectacle Lenses from SightGlass Vision

February 3, 2021—CooperCompanies and EssilorLuxottica announced a partnership to accelerate commercialization of SightGlass Vision spectacle lenses, which are designed to slow the progression of myopia in children, according to press releases from the companies.

Myopia is projected to affect the vision of approximately five billion people globally by 2050, more than doubling today’s numbers. The goal of this collaboration is to help build a comprehensive optical intervention portfolio to offer effective treatments to the growing number of children impacted by myopia.

SightGlass Vision DOT lenses received the CE Mark Declaration in June 2020, enabling the commercialization across the European Union, United Kingdom and other European Economic Area countries. The lenses are also approved in Canada.

SightGlass Vision reported data from the multicenter, randomized, controlled CYPRESS clinical study, which included 256 children, age 6 to 10 years old, with myopia between −0.75 D and −4.50 D. Results showed that patients who wore SightGlass Vision Diffusion Optics Technology (DOT) lenses for a 12-month period had clinically stable visual acuity, a significant reduction in myopia progression between 59% and 74%, and a significant reduction in axial length progression between 33% and 50% compared with the control group.

“This groundbreaking collaboration only adds to our confidence about the future of the technology, the potential for the category and the millions of children whose myopia progression could be slowed.”

- Thomas Chalberg, PhD, SightGlass founder and CEO